Super-resistant *Plasmodium falciparum* threatens the effectiveness of sulfadoxine–pyrimethamine in intermittent preventive treatment for malaria during pregnancy. It is characterized by the A581G *Pfdhps* mutation on a background of the double-mutant *Pfdhps* and the triple-mutant *Pfdhfr*. Using samples collected during 2004–2008, we investigated the evolutionary origin of the A581G mutation by characterizing microsatellite diversity flanking *Pfdhps* triple-mutant (437G+540E+581G) alleles from 3 locations in eastern Africa and comparing it with double-mutant (437G+540E) alleles from the same area. In Ethiopia, both alleles derived from 1 lineage that was distinct from those in Uganda and Tanzania. Uganda and Tanzania triple mutants derived from the previously characterized southeastern Africa double-mutant lineage. The A581G mutation has occurred multiple times on local *Pfdhps* double-mutant backgrounds; however, a novel microsatellite allele incorporated into the Tanzania lineage since 2004 illustrates the local expansion of emergent triple-mutant lineages.

Controlling and reducing malaria requires a combination of vector control measures and administration of antimalarial drugs as prophylaxis or treatment (1). The widespread use of antimalarial drugs has resulted in the emergence of resistant *Plasmodium falciparum*, recurrently exposing persons in malaria-endemic regions to an unacceptably high risk for treatment failures (2).

Highly chloroquine-resistant parasites spread from Asia in the 1960s and led to devastating rates of malaria-related death in Africa starting in the late 1980s, gradually forcing affected countries to replace chloroquine with sulfadoxine–pyrimethamine (SP) (3–5). The effectiveness of SP did not last long. In fact, retrospective analysis indicated that pyrimethamine-resistant parasites were present in sub-Saharan Africa before SP was implemented as first-line treatment, probably because pyrimethamine as mono-therapy had been used in Asia during the 1960’s and 1970’s (6–8). Resistance to sulfadoxine also soon emerged (9), and the combination of pyrimethamine- and sulfadoxine-resistant parasites led to severe and widespread SP treatment failure (10–12). As a consequence, affected countries were once again forced to change their drug policies (13) and have now adopted artemisinin-based combination therapies as first-line treatment for uncomplicated malaria. Yet, SP is still recommended for use as intermittent preventive treatment in pregnant women (SP-IPTp) and infants (SP-IPTi) (14,15). Also, seasonal malaria chemoprevention applies SP in combination with amodiaquine (16). Use of SP for prevention in many countries of sub-Saharan Africa, where clinical failure after SP treatment has been reported, underscores the need for effective surveillance of its protective efficacy and for monitoring of the development and spread of SP resistance in *P. falciparum* populations.

The molecular basis of SP resistance is a combination of single-nucleotide polymorphisms (SNPs) in 2 distinct
genes coding for the target enzymes of SP. The enzymes dihydrofolate reductase (DHFR) and dihydropteroate synthetase (DHPS) are targeted by pyrimethamine and sulfadoxine, respectively (17). High-level pyrimethamine resistance is generally encoded by 3 mutations in the Pf\textit{dhfr} gene, coding for substitutions: N51I, C59R, and S108N (18); the molecular basis of sulfadoxine resistance is caused by substitutions S/A436F, A437G, K540E, A581G, and A613S/T in a variety of combinations in DHPS (19).

The most prevalent genotype in eastern Africa is a combination of the Pf\textit{dhfr} triple mutant (51I, 59R, and 108N, denoted as IRN) combined with the Pf\textit{dhps} double mutant (S436, 437G, 540E, A581, and A613, denoted as SGEAA). Together, this combination of SNPs is referred to as the “quintuple” mutant Pf\textit{dhfr}/Pf\textit{dhps} genotype and is associated with high risk for SP treatment failure (17) and results in limited protective value of SP-IPTi (20). Accordingly, the World Health Organization (WHO) recommends that SP-IPTi should be implemented only when the prevalence of the K540E mutation (and thus the quintuple mutant) is <50% (14).

More recently, an alanine to glycine mutation at codon position 581 in Pf\textit{dhps} has emerged that, in combination with the Pf\textit{dhfr} triple-mutant allele IRN, was shown to confer higher level resistance (21). This combination, referred to as the “sextuple” Pf\textit{dhfr}/Pf\textit{dhps} mutant genotype or the “super-resistant genotype” (22), is associated with reduced SP-IPTp efficacy by 1) a reduction in the protection period of SP-IPTp from 4 weeks to 2 weeks (23); 2) increased parasitemia attributed to competitive facilitation (23); 3) increased risk for severe malaria in the offspring (24); and 4) low birthweight in newborns from mothers undergoing SP-IPTp in Tanzania (25). Consequently, WHO recommendations concerning the use of SP-IPTp base the threshold on 2 mutations: SP-IPTp should be discontinued if the prevalence of the K540E mutation is >95% and the A581G mutation is >10% (20). No threshold in the prevalence of molecular markers of resistance has been set with regard to seasonal malaria chemoprevention (15,16).

Maps collating all published data from molecular surveillance of Pf\textit{dhfr} and Pf\textit{dhps} mutations (22) indicate 3 main foci of super-resistant parasites: 1 in northern Tanzania (26); a second in southwestern Uganda, Rwanda, and bordering areas of Democratic Republic of Congo (27–29); and a third in western Kenya (30). Prevalence of A581G also is high in Ethiopia and northern Sudan, where it again occurs as the Pf\textit{dhps} triple-mutant allele SGEA but in combination with a Pf\textit{dhfr} double-mutant allele 51I-108N.

Assessments of microsatellite variation linked to Pf\textit{dhps} have shown that limited microsatellite diversity flanking the SGEAA double mutants compared with the SAKAA wild types. Two SGEAA lineages were discovered in eastern Africa: 1 prevailing in northeastern Africa (Ethiopia and Sudan) and the other throughout southeastern Africa. Both lineages derived from independent ancestry (10). Here we apply the same approach, using the same microsatellite loci, to determine the ancestry and possible relationship between the double SGEAA and triple SGEA alleles in Ethiopia, Uganda, and Tanzania.

By focusing on microsatellite variation linked to Pf\textit{dhps}, we can explore whether the emergence of the SP-IPTpthreatening SGEA triple mutants in Ethiopia, Uganda, and Tanzania derive from local SGEAA alleles or are being imported.

**Materials and Methods**

**Study Sites**

Samples for the study were collected during 2004–2008. Study sites were in Uganda (2 sites), Tanzania (3 sites), and Ethiopia (1 site) (Table).

**Sample Collection**

**Bufundi and Rikungiri, Uganda**

Uganda implemented SP-IPTp in 2000 and has not implemented SP-IPTi or seasonal malaria chemoprevention. Finger-prick blood-spot samples were obtained from symptomatic patients of all ages after *P. falciparum* infection was confirmed by a Paracheck rapid test (Orchid Biomedical Systems, Chennai, India) during May–December 2005 at reference health facilities in Bufundi (Kabale District) (38 samples) and Kebisoni (Rukungiri District) (27 samples).

**Korogwe, Tanzania**

Korogwe, Tanzania (35 samples) and Magoda, Tanzania (7 samples) were collected from mothers undergoing SP-IPTp in Tanzania (25).Consequently, WHO recommendations concerning the use of SP-IPTp base the threshold on 2 mutations: SP-IPTp should be discontinued if the prevalence of the K540E mutation is >95% and the A581G mutation is >10% (20).

<table>
<thead>
<tr>
<th>Study site</th>
<th>No. samples</th>
<th>Haplotypes diversity</th>
<th>No. samples</th>
<th>Haplotypes diversity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethiopia, Humera, Tigray</td>
<td>35</td>
<td>4</td>
<td>41</td>
<td>1</td>
</tr>
<tr>
<td>Uganda</td>
<td>24</td>
<td>5</td>
<td>14</td>
<td>3</td>
</tr>
<tr>
<td>Bufundi, Kabale</td>
<td>5</td>
<td>27</td>
<td>5</td>
<td>14</td>
</tr>
<tr>
<td>Kebisoni, Rukungiri</td>
<td>7</td>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tanzania</td>
<td>21</td>
<td>6</td>
<td>15</td>
<td>3</td>
</tr>
<tr>
<td>Hale, Tanga</td>
<td>64</td>
<td>21</td>
<td>19</td>
<td>3</td>
</tr>
<tr>
<td>Korogwe, Tanga</td>
<td>7</td>
<td>3</td>
<td>15</td>
<td>6</td>
</tr>
<tr>
<td>Magoda, Tanga</td>
<td>6</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*By country, district, village. Samples from Ethiopia are from 2004; samples from Uganda are from 2005; and samples from Tanzania are from 2004 (Korogwe only), 2006 (Korogwe and Hale), 2007 (Korogwe only) and 2008 (Magoda only).
Hale, Korogwe, and Magoda, Tanzania

Tanzania implemented SP-IPTp in 2001 and has not implemented SP-IPTi or seasonal malaria chemoprevention. Samples were obtained from 3 different settings in Tanga region. From Hale (36 samples), finger-prick blood-spot samples were taken from symptomatic children 6–59 months of age who attended Hale Health Centre during July–August 2006 as previously described (21). The study protocol was approved by the Ethics Review Committees of the National Institute for Medical Research, Tanzania, and the London School of Hygiene and Tropical Medicine and was registered as a clinical trial with the National Institutes of Health (http://www.clinicaltrials.gov, identifier NCT00361114). From Korogwe (83 samples), finger-prick or venous blood samples were obtained on filter paper from children and adolescents <20 years of age from Mkokola and Kwamasimba villages. Samples were collected in March 2004, May 2006, and May 2007, as described (26). The Medical Research Coordinating Committee of the National Institute for Medical Research and Ministry of Health, Tanzania, granted ethical clearance for the study. All participants or their parents or guardians provided informed consent. Samples from Magoda villages (22 samples) were collected from children <5 years of age in June 2008 as part of a cross-sectional assessment of malaria prevalence (31).

Humera, Ethiopia

Ethiopia has adopted neither of the WHO recommendations regarding use of SP as prophylaxis. Samples were collected from patients of all ages who attended Kahsay Abera Hospital in Humera during January–April 2004 and who had symptomatic uncomplicated malaria (10). The patients were enrolled in an in vivo efficacy trial, comparing artemether–lumefantrine therapy with SP therapy, which was conducted by staff of Kahsay Abera Hospital and the Mekele Regional Health Bureau. Finger-prick blood-spot samples were taken from patients before treatment after they gave written informed consent to participate in the study, and genetic analysis was conducted in support of the drug efficacy evaluation. The Ethical Clearance Committee of the Tigray Health Research Council and the external Ethics Review Board used by Médecins sans Frontières gave ethical permissions for the study.

Genotyping

Sample collection at the different study sites was not standardized because the samples derived from independent studies. However, all samples consisted of finger-prick blood spots stored on filter paper, and parasite DNA was extracted by using the Chelex method (32).

Point mutations in samples from Hale, Tanzania, were determined by direct sequencing (21). Sequencing was performed by using the ABI-3730 automatic sequencer (Applied Biosystems, Foster City, CA, USA), and samples were analyzed with Applied Biosystems BigDye V. 3.1 (Applied Biosystems).

For all other samples, the polymorphic region of Pfhdps was PCR-amplified before sequence-specific oligonucleotide probing (SSOP) for mutations at codons 436, 437, 540, 581, and 613 by using primers and PCR conditions described elsewhere (33). SSOP-genotyping of samples from Uganda and Ethiopia was conducted according to an SSOP–dot-blot method (10); genotyping of samples from Korogwe and Magoda in Tanzania was conducted according to an SSOP-ELISA method (33).

Only samples containing the Pfhdps SGEAA or SGEGA alleles were included for further analysis; other alleles, such as wild-type or single-mutant alleles, were excluded. In general, only a single sequence was detected at every codon, but if the sequence analysis detected a mixture, these samples were handled as mixed infections. Mixed infections, in turn, were further analyzed only if 1 allele was substantially in the majority (i.e., a 2:1 signal ratio between the dominant genotype and the minor genotype) and a majority SNP could be confidently determined at all codon positions (33).

Microsatellite Analysis

Analysis was performed on 3 Pfhdps-linked microsatellites located 0.8 kb (marker [m.] 0.8), 4.3 kb (m. 4.3), and 7.7 kb (m. 7.7) downstream of the coding position 437 of Pfhdps, located on chromosome 8 (34). Microsatellites were amplified by seminested PCR as described previously (34), and products were run with GeneScan-500 LIZ Size Standards (Applied Biosystems) in an ABI 3730 DNA analyzer (Applied Biosystems) and analyzed by using Genemapper software (Applied Biosystems). If>1 microsatellite allele was detected in any given sample, the peak height ratio was used to determine the majority allele for that locus. If the major allele did not have a peak height of at least double the height of the minor allele, the sample was excluded from further analysis.

Microsatellite haplotypes were constructed by combining alleles detected in each of the 3 microsatellite loci. Samples with missing data were not included.

Results

A total of 300 samples with either Pfhdps double-mutant (SGEAA) or triple-mutant (SGEGA) alleles were
subjected to microsatellite analysis, and 277 (92.3%) of
these gave conclusive results. Microsatellite haplotypes
associated with the \( Pfdhps \) double- and triple-mutant alleles
are listed in full (online Technical Appendix Table, [link](http://wwwnc.cdc.gov/EID/article/20/8/13-1897-Techapp1.pdf)),
where the haplotypes are ranked hierarchically according
to allele size, first at the 0.8-kb locus, then at 4.3-kb locus,
and finally at the 7.7-kb locus, and each unique haplotype
was assigned a number.

**Diversity of Microsatellite Composition among
SGEAA Samples**

SGEAA alleles from Ethiopia were associated with
4 different microsatellite haplotypes (Figure, panel A;
Table). Haplotype 4 (notation 121–114–98, refers to frag-
ment size 121 bp at the 0.8-kb locus, 114 bp at the 4.3-kb
locus, and 98 bp at the 7.7-kb locus) predominated and was
found in 30 (85.7%) of the 35 SGEAA alleles sampled. Of
the remaining 3 microsatellite haplotypes, haplotypes 7 and
21 were each found twice; 11 was found once. Haplotype
11 (131–104–107) was most common in the samples from
Uganda and Tanzania. No samples from Tanzania or Ugan-
da were Ethiopia haplotype 4. The Uganda SGEAA alleles
were associated with 8 different microsatellite haplotypes
(Figure, panel A; online Technical Appendix Table, 5 hap-
lotypes found at each site); the most common haplotype,
haplotype 11 (131–104–107), was found in 82.4%, (42/51)
of samples. The 92 SGEAA samples collected from 3 study
sites in Tanzania exhibited 24 different microsatellite hap-
lotypes (Figure, panel A; online Technical Appendix Ta-
ble). Korogwe exhibited the greatest diversity by having 21
haplotypes among 64 SGEAA sample. As in Uganda, most
of the Tanzania SGEAA alleles were associated with hap-
lotype 11 (53 [57.6%]). Among the remaining 39 samples
were 23 alternative but related haplotypes.

**Diversity of Microsatellite Composition among
SGEGA Samples**

Of 41 SGEGA samples from Ethiopia, only 1 micro-
satellite haplotype was present: haplotype 4 (121–114–98)
(Figure, panel B; online Technical Appendix Table). The
28 SGEGA samples from Uganda were associated with
3 microsatellite haplotypes; all 3 combinations were
represented in the 2 sites (Figure, panel B; online Appendix
Table). Of these SGEGA samples, 24 (85.7%) were hap-
lotype 11 (131–104–107). The 2 less common haplotypes,
haplotype 18 (131–104–125) and 14 (131–104–113), are
evidently related to haplotype 11, differing by 1 allele at
the 7.7-kb locus. Of 49 SGEGA samples collected from
Tanzania, we found 7 microsatellite haplotypes (Figure,
panel B; online Technical Appendix Table). This finding
indicates less diversity than was associated with SGEAA
alleles: Hale (3 haplotypes), Korogwe (3 haplotypes), and
Magoda (6 haplotypes). Of the Tanzania SGEGA samples,
18 (36.7%) were haplotype 11, the same haplotype com-
mon among Tanzania and Uganda SGEEA samples and
among Uganda SGEEA samples. Of the remaining 28
SGEGA samples from Tanzania, 24 (49.0% of total Tanza-
mnia SGEEA samples) were haplotype 18 (131–104–125),
a haplotype found only twice in association with SGEAA
samples from Tanzania. This haplotype was found twice
among Uganda SGEAA samples and never among Uganda
SGEEA samples.

**Discussion**

Although SP is no longer recommended as first-line
treatment for \( P. falciparum \) infection, it is widely recom-
ended for prevention and possibly still available over the
counter for self-treatment. Presumably, therefore, SP has
continued to exert selective pressure on already resistant
parasites, which might explain the continuing emergence
of the triple-mutant \( Pfdhps \) allele (SGEGA), which is cur-
rently being described for certain regions of eastern Africa.
An increased prevalence of the A581G mutation has been well documented in eastern Africa in recent years; it increased from 12% in 2003 to 56% in 2007 at study sites in Korogwe, Tanzania (26). In Kabale and Rukungiri, Uganda, samples from 2005 showed a high prevalence of the A581G mutation at 45% and 46%, respectively (27); studies during 2005–2006 in Rukara and Mahesha, Rwanda, observed prevalences of 60% and 29%, respectively (28). A study in 2010 in Huye District, Southern Province, Rwanda, reported a prevalence of 63% (35). In eastern Sudan, a study found an increase in the prevalence of the A581G mutation from 14% in 2003 to 34% in 2012 (36). In Kenya, Kisumu, a study showed an increase in the A581G mutation from 0% in 1999–2000 to 85% in 2003–2005 (30). More recently, in Nyanza Province, western Kenya, the prevalence of the A581G increased from 0% to 5.3% from 2008–2009 (37).

In this study, we investigated the origins of triple-mutant PfΔhps alleles by analyzing the microsatellite diversity flanking PfΔhps. We sampled both SGEAA double mutants and SGEGA triple mutants in 3 populations at the key moment: when the SGEGA triple mutant had emerged but had not yet replaced the SGEAA double mutant. At this time, double- and triple-mutant alleles were present in similar numbers in the areas, but SP-sensitive alleles were very rare.

In Ethiopia, both SGEAA and SGEGA alleles were associated with haplotype 4 (121–114–98), indicating a shared ancestry that has evolved independently from SGEAA and SGEGA alleles from Uganda and Tanzania. The SGEAA in these 2 countries were associated with lineage 11 (131–104–107), the same microsatellite haplotype previously shown to be associated with the double-mutant alleles throughout Tanzania, Kenya, Uganda, Mozambique, and Zambia (10).

In Ethiopia and Uganda, we found evidence that the most prevalent SGEAA haplotype locally had given rise to SGEAA haplotypes in the same area; the most common SGEAA haplotype was also the most common SGEGA haplotype in both countries (haplotypes 4 and 11, respectively). However, in Tanzania, the microsatellite haplotype most commonly associated with SGEGA (haplotype 18 [131–104–125], 25/49 samples) was not identical to that most commonly associated with SGEAA (haplotype 11 [131–104–107]), because only 2 SGEAA samples were haplotype 18. This finding leads us to speculate that the A581G mutation has emerged on at least 2 occasions in Tanzania.

We found that the microsatellite diversity associated with both SGEAA and SGEGA haplotypes in Ethiopia samples was less than in the SGEAA and SGEGA samples from sites in Uganda and Tanzania. The high level of homozygosity among microsatellite haplotypes in Ethiopia might be due to a high degree of selective pressure, which in turn might be assisted by population bottlenecks brought about by a narrow malaria transmission season and limited exchange of parasites, with neighboring regions resulting from limited migration. The Ethiopia samples originate from the Tigray District near the Eritrean border. Despite some migration of refugees from Eritrea to Ethiopia, a substantial spread to and from the Tigray District in Ethiopia during the years before sample collection is doubtful because of the continued presence of forces at the border during the cease fire succeeding the Eritrean–Ethiopian war initiated in 2000. Double- and triple-mutant alleles from northeastern and eastern Sudan also are associated with haplotype 4 (121–114–98) (10) and represent greater diversity than what we present from Ethiopia, which supports the view that the parasite populations in these 2 countries are linked (10,38).

Tanzania is a capital of trade and emigration for sub-Saharan Africa. The Tanzam highway (running from Tanzania through Zambia) is one of the most trafficked roads on the African continent, and higher diversity and sharing of common microsatellite haplotypes among the Ugandan and Tanzanian populations were therefore expected. A recent publication about the correlation between human population movement and malaria movement in Uganda, Tanzania, and Kenya (39) illustrates that the major human population movement and malaria movement in Tanzania originates from central Dodoma and directs northward and westward. In this regard, an early selection of a haplotype in the Tanga region (northeast) compared with other areas of Tanzania, can be speculated to be plausible because of the larger levels of parasite migration to northern and western parts of the country, diluting to some extent the newly selected haplotypes in these areas.

In conclusion, we provide evidence that the A581G mutation can arise on various SGEAA ancestral backgrounds, of which we have shown 3 different cases (haplotypes 4, 11, and 18), from areas previously known to represent 2 distinct parasite lineages. Our microsatellite analysis is consistent with reports that the SGEGA triple-mutant alleles are undergoing rapid expansion, and we found evidence of spread of the Tanzania SGEGA haplotype (haplotype 18) as far as southwestern Uganda, which illustrates the potential for dispersal of super-resistant P. falciparum malaria throughout the region. Given the rate of increase and the ability of double-mutant allele lineages to acquire the super resistance–conferring A581G mutation independently, it is vital for the continuing effectiveness of prophylaxis with SP that more comprehensive surveillance for the A581G mutation be used to track emerging super-resistant malaria in Africa.

Acknowledgments

Médecins Sans Frontières was responsible for the in vivo study in Humera, Ethiopia, and made samples available for this
study. We thank Ambachew Medhin, Ato Assefaw, and Manica Balasegaram for their participation in this research project. We thank Tarekegn A. Abeke for his work in the Uganda study. Collaboration partners in Tanga, Tanzania, are acknowledged for long-term collaboration resulting in many studies, as well as the samples and study presented here. We thank Ulla Abildrup for excellent technical assistance in performing some of the SSOP-ELISA analyses.

The study was financially supported by the Gates Malaria Partnership and Danish International Development Agency.

Dr Alifrangis is an associate professor at the faculty of Health and Medical Sciences of the University of Copenhagen. His primary research interest is the use of molecular markers as tools to monitor and possibly hinder emergence and spread of drug resistance in malaria-endemic regions.

References

24. Harrington WE, Morrison R, Fried M, Duffy PE. Intermittent preventive treatment in pregnant women is associated with increased risk of severe malaria in their offspring. PLoS ONE. 2013;8:e56183. http://dx.doi.org/10.1371/journal.pone.0056183

Address for correspondence: Sidsel Nag, Center for Medical Parasitology, 7680 CSS Bldg 22, Bartholinsgade 2 1356 København K, Denmark; email: sidselnag@sund.ku.dk

June 2014:
Respiratory Infections
Including:
• Adverse Pregnancy Outcomes and Coxiella burnetii Antibodies in Pregnant Women, Denmark
• Short-Term Malaria Reduction by Single-Dose Azithromycin during Mass Drug Administration for Trachoma, Tanzania
• Human Polyomavirus 9 Infection in Kidney Transplant Patients
• Genetic Evidence of Importation of Drug-Resistant Plasmodium falciparum to Guatemala from the Democratic Republic of the Congo
• Characteristics of Patients with Mild to Moderate Primary Pulmonary Coccidioidomycosis
• Rapid Spread and Diversification of Respiratory Syncytial Virus Genotype ON1, Kenya

http://wwwnc.cdc.gov/eid/articles/issue/20/6/table-of-contents